NCT06160414View on ClinicalTrials.gov

A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

February 5, 2024

Study Completion Date

February 5, 2024

Conditions
Healthy
Interventions
DRUG

Metformin

Participants will receive Metformin orally, after fasting.

DRUG

Rosuvastatin

Participants will receive Rosuvastatin orally, after fasting.

DRUG

ALXN2080

Participants will receive ALXN2080 orally, after fasting.

Trial Locations (1)

NG11 6JS

Research Site, Ruddington

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY